Self-screen B.V. is a molecular screening and diagnostic testing company from the Netherlands. Its core mission is to help healthcare institutions and clinicians identify the risk of cervical cancer and precancerous lesions earlier. Its focus is not SaaS or enterprise software, but laboratory products such as HPV screening, methylation-based molecular tests, research-use assays, and quality-control samples.
The main products shown on the website include HPV-Risk Assay/QIAscreen HPV PCR Test, used to detect 15 high-risk or potentially high-risk HPV genotypes; PreCursor-M+/QIAsure Methylation Test, designed to identify women with cancer-like methylation characteristics and a higher short-term risk of progression; PreCursor-M AnoGYN, intended for research into ASCL1 and ZNF582 methylation levels in anal samples; PreCursor-M Gold, currently for Research Use Only, for studies on detecting high-grade precancerous lesions and cervical cancer in HPV-positive women; and Methylated DNA Control Sample for quality control in MSP workflows.
The collected content does not disclose pricing, plans, payment methods, trials, or procurement processes. It also does not provide enterprise software information such as cloud deployment, self-hosting, account permissions, or APIs. In terms of third-party platforms, the text mentions that PreCursor-M AnoGYN can be developed as a multiplex quantitative methylation-specific PCR assay on PCR instrument platforms such as RotorGeneQ, Mic, and ViiA7. However, this is adaptation to laboratory instruments and testing workflows, not software integration.
Its strengths lie in a clearly focused product portfolio covering primary HPV screening, triage of HPV-positive populations, methylation testing, and quality control. It also emphasizes objective, reproducible, high-throughput, fully molecular automated cervical screening. Its testing approach also aims to reduce overtreatment of non-progressive lesions. The limitation, from a SaaS perspective, is that the website provides almost no information on software features, permission-based collaboration, security certifications, service support, or pricing transparency. Some products are still at the research-use stage, so their clinical applicability requires further confirmation.
It is better suited for molecular diagnostic laboratories, medical screening programs, research institutions, and clinical partners evaluating relevant testing solutions. It is not suitable for users looking for general-purpose enterprise software or SaaS platforms. The text does not provide information on access from China, and payment or localization support is also unclear. For deployment in China, it would be important to compare it with locally approved alternatives for HPV testing, cervical cancer screening, and methylation-based testing.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on self-screen.nl official site.
self-screen.nl is an Netherlands SaaS Tools provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach self-screen.nl directly.